Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Daiichi Sankyo And MorphoSys Expand Collaboration With Two New Cancer-Related Antibody Programs
MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) announced the start of a further two oncology-focused therapeutic antibody programs within its collaboration with DAIICHI SANKYO COMPANY, LIMITED (TSE: 4568, hereinafter Daiichi Sankyo). By exercising two options available under the parties" existing agreement, Daiichi Sankyo has selected two new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL technology. Daiichi Sankyo will carry out pre-clinical and clinical development and has worldwide marketing rights for all resulting products. MorphoSys receives exclusive license fees and stands to receive milestones and royalties for the therapeutic antibody programs, as per the terms of the companies" existing agreement. Further financial details were not disclosed.

How Do I Know If I Need Knee Replacement Surgery?
Most knee replacement patients are between the ages of 60 and 80 years old. In some cases, younger patients with traumatic knee injuries may also require a total knee replacement. However the most common diagnosis is osteoarthritis. If you are prevented from carrying out your everyday activities due to pain or discomfort in the knee, then you may have arthritis of some kind. Similarly, difficulty in bending, squatting, kneeling, and walking may be indications that a knee replacement is in your future.
News of the day
Stem Cell Discovery May Bring Tissue Repair Closer
The goal of creating adult blood stem cells from human embryos to prepare a patient for tissue and organ transplant has been brought a step closer by research carried out at the MRC Molecular Haematology Unit at Oxford University.
Oncology

Xenophon Attacks South Australian Aged Care Nurses

Australian Nursing Federation (ANF) Federal Secretary Ged Kearney said comments made by Senator Nick Xenophon today display a lack of understanding of the award modernisation process and the benefits this process brings to nursing staff, employers and the aged care industry. Ms Kearney said a media release issued by Senator Xenophon, calling on the government to delay the introduction of a new award in aged care was an ill-considered acceptance of economic modelling prepared by South Australian aged care employers. "The Senator"s comments show he has little understanding of the funding or employment arrangements that apply to the aged care industry," Ms Kearney said. "The employer costings he cites have been around for a number of months now and no one accepts them because upon closer examination they are obviously flawed and misleading. It is disappointing that Xenophon appears to have accepted the modelling without question." "The new award will provide nursing staff with an equitable safety net and Senator Xenophon should support the dedicated nurses who care for some of the most vulnerable members of our community." It is well known that nurses working in aged care across the country earn on average 20% or $300 per week less than nurses in other sectors of health. "Why should nursing staff working in aged care be denied a decent award and fair pay because the sector is under funded." Ms Kearney said the ANF is currently campaigning for pay equity for nursing staff in aged care and as the representative of 170,000 nurses and midwives in Australia invites Senator Xenophon to work with industry representatives to ensure that aged care workers are adequately paid and that residents continue to receive quality nursing care. Australian Nursing federation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009